Fuisz Pharma Announces Acquisition of Key Anti Opiate Abuse Patent to Complement its Anti Opiate Abuse Platform
MIAMI, July 12 /PRNewswire/ — Fuisz Pharma today announced that it has acquired a key issued patent (US 7,214,385 “Pharmaceutical Formulation Containing Dye” (invented by Dr. Thomas Gruber)). This patent covers the use of dyes and staining agents in pharmaceutical dosage forms as a method to prevent the improper use of opiate derived drugs by visually demonstrating their misuse.
Fuisz Pharma President, Joseph Matus Fuisz commented: “The technology described in the acquired patent is highly complementary to the anti abuse portfolio that we previously announced. Importantly, the Gruber patent enables us to offer strong, existing patent protection for our partners. We thus believe that this acquisition significantly enhances the value of our anti abuse platform and gives us a very strong IP position in the prevention of opiate abuse.”
Mr. Fuisz continued: “This acquisition is also complementary to our next generation technology to aid and abet the absorption of all dosage forms including the ability to bring forth a very novel methodology to specifically play a critical role in the opiate agonist/antagonist pas de deux. This methodology is applicable to all dosage forms.”
Noted pharmaceutical inventor Richard C. Fuisz, M.D. (http://en.wikipedia.org/wiki/Richard_Carl_Fuisz) is one of the principals of Fuisz Pharma.
Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma. Fuisz Pharma has its headquarters in Miami. www.fuisz.com.
SOURCE Fuisz Pharma